Senores Pharma. (SENORES)

FairStock Score: 38/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Exceptional sales and profit growth of 69.44% and 84.28% respectively
• Low debt-to-equity of 0.29 indicates a conservative balance sheet
• Piotroski F-Score of 7/9 suggests solid financial health and improving operations
• Healthy latest quarter net profit margin of ~19% on sales of ₹175 Cr
• PEG ratio of 0.45 implies growth is not fully reflected in valuation

Concerns

• High valuation: P/E of 34.67 and P/B of 5.48 leave little room for error
• ROCE of only 11.40% is modest for such a high-growth pharma player
• No dividend yield – total return relies entirely on capital gains
• Recent price volatility (52W range ₹662.45 - ₹1510.70) suggests uncertainty

AI Analysis

When I look at Senores Pharma, I see a company growing at a pace that would make even a growth investor blink. Sales up 69.44% and profits up 84.28% – that is impressive. But as Graham taught us, growth is only meaningful if it is backed by financial strength and a durable moat. The balance sheet looks manageable: debt-to-equity at 0.29 and ROCE at 11.40%, which is decent but not exceptional. Book value of ₹164.41 against a price of ₹900.65 means I am paying over five times book for this business. That is a steep price, and it demands a lot of future perfection. The P/E of 34.67 is rich, though the PEG ratio of 0.45 suggests the market is not fully pricing in the current earnings momentum. Still, I must be cautious. Promoter holding of 45.80% is reasonable, but not a controlling lock that some quality franchises show. The Piotroski score of 7/9 tells me the company is improving operationally, which is good. But the FairStock score of 42/100 warns me that not everything is rosy. The 52-week range – from ₹662 to ₹1510 – shows the stock has been volatile, and I don't like paying a high price for a business in a cyclical industry like pharma, where regulatory and competitive risks are never far away. The latest quarter sales of ₹175 Cr and net profit of ₹34 Cr imply a margin of about 19%, which is healthy. Yet with no dividend, my return depends entirely on capital appreciation and continued high growth. I would only consider this if I believed the growth is sustainable for many years, and at this price, I need a very large margin of safety. Right now, I see a fast grower, but not a bargain.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer